Early and accurate detection of clinically significant prostate cancer is critical—and OnQ™ Prostate is redefining the standard. Using Restriction Spectrum Imaging (RSI), this FDA-cleared software improves tumor characterization and enhances differentiation between cancerous and non-cancerous tissue, helping both experts and novices achieve more confident diagnoses. Fill out the form below to watch: